Document is current
Any future updates will be listed below
-
Authors
Yamamoto, Toshiyuki https://orcid.org/0000-0002-8390-2573
Tanizaki, Hideaki
Yamasaki, Kenshi https://orcid.org/0000-0002-5495-4956
Matsubara, Naoko https://orcid.org/0000-0003-2668-4853
Nakayama, Masahiko
Iwashita, Eri https://orcid.org/0009-0002-5176-8493
Yamanaka, Keiichi https://orcid.org/0000-0003-3055-5202
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04750213 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and Effectiveness of Adalimumab for the Treatment of Pyoderma Gangrenosum: A 52-Week Real-World Prospective Observational Study
https://doi.org/10.1007/s13555-026-01772-4
-
Funding
Funding for this research was provided by:
AbbVie GK
- License Information
-
More Information
Article History
Received: 22 December 2025
Accepted: 17 April 2026
First Online: 10 May 2026
Declarations
:
: Toshiyuki Yamamoto received speaker or consulting fees from AbbVie. Hideaki Tanizaki received honoraria from AbbVie, Sanofi, Eli Lilly, Maruho, Sun Pharmaceutical Industries Limited, Mitsubishi Tanabe, Janssen, Torii, and Kyowa Kirin; contract research and collaborative research funding from Sun Pharmaceutical Industries Limited, Eisai, Maruho, and AbbVie; and scholarship donations from Sun Pharmaceutical Industries Limited, Eisai, Maruho, Taiho Pharmaceutical, Torii, Kyowa Kirin, Mitsubishi Tanabe, UCB, and Eli Lilly. Kenshi Yamasaki received research grants from AbbVie during the conduct of the study; research grants from Kao Corporation and Estee Lauder; consulting fees from Pola Chemical Corporation; and honoraria for lectures from Maruho, Sato Pharmaceutical, Eli Lilly Japan, UCB Japan, AbbVie, Taiho Pharmaceutical, Sun Pharmaceutical Industries Limited, Novartis, Eisai, Boehringer Ingelheim Japan, Bristol Myers, Grafa Laboratories Corporation, and Sanofi. Naoko Matsubara, Masahiko Nakayama, and Eri Iwashita are employees of AbbVie GK. Keiichi Yamanaka received research grants from Eli Lilly Japan, Leo Pharma, Maruho, Sasaki Chemical, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, KAKENHI, Nihon Kayaku, Kaken Pharmaceutical, Nihon Seiyaku, Boehringer Ingelheim, and Otsuka Pharmaceutical and lecture fees from AbbVie, Otsuka Pharmaceutical, Astellas Seiyaku, Boehringer Ingelheim, Pfizer, Celgene, UCB Japan, Daiichi-Sankyo, Bristol Myers, Eisai, Kaken Pharmaceutical, Eli Lilly Japan, Nobel Pharma, Janssen, Kyowa Kirin, Leo Pharma, Maruho, Mitsubishi Tanabe, Nippon Kayaku, Nippon Zouki, Novartis, Sato Seiyaku, Sanofi, Sun Pharmaceutical Industries, Taiho Pharmaceutical, and Torii Pharmaceutical.
: The study protocol was reviewed and authorized by the Pharmaceuticals and Medical Devices Agency. Although not strictly required by the GPSP, ethical approval from institutional review boards or ethics committees of the participating medical centers was obtained when required. Patients or their legal guardians provided informed consent to participate in the study prior to initiating adalimumab treatment.
